What is the recommended management of skin lesions in a patient being treated with pazopanib?

Management of Pazopanib-Induced Skin Lesions

For skin lesions occurring during pazopanib therapy, the management approach depends on the specific type of dermatologic toxicity: hand-foot skin reaction (HFSR) requires topical high-potency corticosteroids and keratolytics with potential dose modification, while depigmentation is an expected cosmetic effect requiring only patient counseling.

Identifying the Type of Skin Lesion

The FDA label for pazopanib identifies several distinct cutaneous manifestations 1:

• Palmar-plantar erythrodysesthesia (hand-foot syndrome): Occurs in 6% of RCC patients and 11-12% of soft tissue sarcoma patients, with higher rates (up to 6% Grade 3/4) in East Asian populations 1
• Depigmentation: Hair or skin depigmentation occurs commonly and is listed as an expected adverse reaction 1
• Rash and exfoliative rash: General rash occurs in 8% of RCC patients and exfoliative rash in 18% of STS patients 1
• Rare severe reactions: Leukocytoclastic vasculitis 2 and phototoxic reactions 3 have been reported

Management of Hand-Foot Skin Reaction (HFSR)

Grade 1 HFSR (Minimal skin changes or dermatitis)

• Continue pazopanib at current dose and initiate topical therapy 4
• Apply topical high-potency corticosteroid (e.g., clobetasol propionate 0.05%) twice daily 4
• Reassess after 2 weeks; if worsening or no improvement, escalate to Grade 2 management 4

Grade 2 HFSR (Skin changes with pain; limiting instrumental activities of daily living)

• Continue pazopanib at current dose while intensifying topical management 4
• Apply topical high-potency corticosteroid twice daily 4
• Add keratolytic agents for hyperkeratosis: salicylic acid 5%-10% or urea 10%-40% creams 4
• Consider lidocaine 5% cream or patches for painful areas to maintain function 4
• Treat erosions/ulcerations with antiseptic solutions (silver sulfadiazine 1% or polyhexanide 0.02%-0.04%) 4
• Reassess after 2 weeks; if no improvement, proceed to Grade 3 management 4

Grade ≥3 or Intolerable Grade 2 HFSR

• Interrupt pazopanib until severity decreases to Grade 0-1 4
• Continue aggressive topical therapy with high-potency corticosteroids and keratolytics 4
• Reassess after 2 weeks; if no improvement, dose reduction or permanent discontinuation may be necessary 4

Critical caveat: Pazopanib significantly impairs wound healing through inhibition of angiogenesis and cell proliferation. A case report demonstrated that a surgical wound deteriorated for 4 months on pazopanib but healed within 2 months after discontinuation 5. Therefore, discontinue pazopanib at least 1 week before any surgical procedure and do not resume for at least 2 weeks post-surgery until adequate wound healing occurs 1.

Management of Depigmentation

• No intervention required beyond patient counseling 1
• Inform patients that depigmentation of hair or skin is an expected cosmetic effect that does not require dose modification 1
• This is distinct from post-inflammatory hyperpigmentation and does not respond to depigmenting agents 6

Management of Other Rashes

For non-specific rashes or dermatitis:

• Apply low-to-moderate potency topical corticosteroids (e.g., hydrocortisone 2.5%) if residual inflammation is present 4, 6
• Avoid skin irritants, frequent hot water washing, and excessive sun exposure 4
• Use alcohol-free moisturizers with urea 5%-10% at least twice daily 4
• Apply broad-spectrum sunscreen (SPF 15 minimum, UVA/UVB protection) 4

Monitoring for Severe Cutaneous Reactions

While rare, serious skin toxicities require immediate recognition:

• Leukocytoclastic vasculitis: Presents as palpable purpura, typically on lower extremities; requires skin biopsy for confirmation and permanent discontinuation of pazopanib 2
• Phototoxic reactions: Sun-exposed areas develop erythema and pain; manage with sun avoidance and consider discontinuation 3
• Skin ulceration/necrosis: Particularly concerning when pazopanib is combined with radiation therapy (even non-concurrently); may require permanent discontinuation 7

Key Clinical Pitfalls

• Do not rely on corticosteroids alone for HFSR—they address inflammation but keratolytics are essential for hyperkeratosis 4
• Do not continue full-dose pazopanib through Grade 3 skin toxicity, as this compromises quality of life without improving oncologic outcomes 4
• Do not underestimate wound healing impairment: Even minor procedures may result in non-healing wounds requiring prolonged drug holidays 5
• East Asian patients require closer monitoring for severe HFSR (6% Grade 3/4 versus 2% in non-East Asian populations) 1